Publications by authors named "Anna Bucsics"

Claim this Profile
P
Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA.
Maria Cavaller-Bellaubi, Wills Hughes-Wilson, Šárka Kubinová, Marc Van de Casteele, Evert Jan Van Lente, Anna Bucsics

Orphanet J Rare Dis· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria.
Michael Kossmeier, Madeleine Themanns, Lena Hatapoglu, Bernhard Kogler, Simon Keuerleber, Anna Bucsics

Front Pharmacol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Nils Wilking, Anna Bucsics, Lidlija Kandolf Sekulovic, Gisela Kobelt, Andrea Laslop

ESMO Open· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study.
Yuxi Tian, Berthold Reichardt, Daniela Dunkler, Milan Hronsky, Wolfgang C Winkelmayer, Anna Bucsics

Sci Rep· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA.
Patricia Vella Bonanno, Anna Bucsics, Steven Simoens, Antony P Martin, Wija Oortwijn

Expert Rev Pharmacoecon Outcomes Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
Elena Nicod, Lieven Annemans, Anna Bucsics, Anne Lee, Sheela Upadhyaya

Health Policy· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution of adaptiveness: balancing speed and evidence.
Hans-Georg Eichler, Richard Barker, Nicola Bedlington, Jacoline C Bouvy, André W Broekmans, Anna Bucsics

Nat Rev Drug Discov· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C Rothe

Front Public Health· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European challenges of funding orphan medicinal products.
Márta Szegedi, Tamás Zelei, Francis Arickx, Anna Bucsics, Emanuelle Cohn-Zanchetta

Orphanet J Rare Dis· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries.
Tomasz Bochenek, Vafa Abilova, Ali Alkan, Bogdan Asanin, Iñigo de Miguel Beriain, Anna Bucsics

Front Pharmacol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.
Patricia Vella Bonanno, Michael Ermisch, Brian Godman, Antony P Martin, Jesper Van Den Bergh, Anna Bucsics

Front Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.
Michael Ermisch, Anna Bucsics, Patricia Vella Bonanno, Francis Arickx, Alexander Bybau

Front Pharmacol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.
Winnie de Bruijn, Cristina Ibáñez, Pia Frisk, Hanne Bak Pedersen, Ali Alkan, Anna Bucsics

Front Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and determinants of unintended double medication of antihypertensive, lipid-lowering, and hypoglycemic drugs in Austria: a nationwide cohort study.
Georg Heinze, Lisanne M Jandeck, Milan Hronsky, Berthold Reichardt, Christoph Baumgärtel, Anna Bucsics

Pharmacoepidemiol Drug Saf· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LOOKING BACK ON 5 YEARS OF HORIZON SCANNING IN ONCOLOGY.
Anna Nachtnebel, Johanna Breuer, Wolfgang Willenbacher, Anna Bucsics, Peter Krippl

Int J Technol Assess Health Care· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European collaboration on relative effectiveness assessments: What is needed to be successful?
Sarah Kleijnen, Wil Toenders, Folkert de Groot, Mirjana Huic, Elisabeth George, Anna Bucsics

Health Policy· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study.
Georg Heinze, Milan Hronsky, Berthold Reichardt, Christoph Baumgärtel, Marcus Müllner, Anna Bucsics

Appl Health Econ Health Policy· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Brian Godman, Rickard E Malmström, Eduardo Diogene, Andy Gray, Sisira Jayathissa, Anna Bucsics

Expert Rev Clin Pharmacol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Piloting international production of rapid relative effectiveness assessments of pharmaceuticals.
Sarah Kleijnen, Iris Pasternack, Piia Rannanheimo, Jenni M Vuola, Marc Van de Casteele, Anna Bucsics

Int J Technol Assess Health Care· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.
James C Moon, Brian Godman, Max Petzold, Samantha Alvarez-Madrazo, Kathleen Bennett, Anna Bucsics

Front Pharmacol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
Brian Godman, Bjorn Wettermark, Menno van Woerkom, Jessica Fraeyman, Samantha Alvarez-Madrazo, Anna Bucsics

Front Pharmacol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
Brian Godman, Max Petzold, Kathleen Bennett, Marion Bennie, Anna Bucsics

BMC Med· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.
Brian Godman, Rickard E Malmström, Eduardo Diogene, Sisira Jayathissa, Stuart McTaggart, Anna Bucsics

Front Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalizing health care: feasibility and future implications.
Brian Godman, Alexander E Finlayson, Parneet K Cheema, Eva Zebedin-Brandl, Inaki Gutiérrez-Ibarluzea, Anna Bucsics

BMC Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.
Rickard E Malmström, Brian B Godman, Eduard Diogene, Christoph Baumgärtel, Marion Bennie, Anna Bucsics

Front Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis